Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > Targeted nanoparticles incorporating siRNA offer promise for cancer treatment

Abstract:
The use of targeted nanoparticles offers promising techniques for cancer treatment. Researchers in the laboratory of Mark E. Davis at the California Institute of Technology have been using small interfering RNA (siRNA), sometimes known as silencing RNA, to "silence" specific genes that are implicated in certain malignancies. One of the primary challenges associated with this type of therapy is delivering the therapeutic agent into the body and then to the tumor in a safe and effective manner. By using targeted nanoparticles, researchers have demonstrated that systemically delivered siRNA can slow the growth of tumors in mice without eliciting the toxicities often associated with cancer therapies. The results of this research are being presented this week at the NSTI Nanotech 2007 Conference in Santa Clara, CA.

Targeted nanoparticles incorporating siRNA offer promise for cancer treatment

SANTA CLARA, CA | Posted on May 20th, 2007

The Caltech researchers have incorporated siRNA into nanoparticles that are formed completely by self-assembly, characterized the behavior of these nanoparticles and studied their safety and efficacy in mice.

Using extensive physicochemical and biological characterization, the investigators are able to estimate the composition of individual nanoparticles and to correlate the nanoparticle structure with its biological function. This quantitative approach provides unique insights into the design of more effective nanoparticle carriers.

According to the lead author of the study, Derek W. Bartlett, "Safe and effective delivery remains perhaps the greatest impediment to the clinical realization of small interfering RNA (siRNA) in cancer therapy. Formation of siRNA nanoparticles using cyclodextrin-containing polycations is one of the most promising strategies for systemic siRNA delivery, and such nanoparticles are expected to enter Phase I clinical trials by late 2007. Our most recent work examines the impact of various dosing schedules and surface modifications on the efficacy of these siRNA nanoparticles in preclinical cancer models. By combining the experimental data with a mathematical model of siRNA-mediated gene silencing, we illustrate several practical considerations that we believe will be directly relevant to the clinical application of siRNA-based therapeutics in cancer therapy."


The presentation is "Characterization and in vivo efficacy of targeted nanoparticles for systemic siRNA delivery to tumors" by D.W. Bartlett and M.E. Davis, from the California Institute of Technology. It will be presented at the NSTI Nanotech 2007 conference in Santa Clara, CA on May 21, 2007, 4:40 PM, Great America 3, Santa Clara Convention Center.

####

For more information, please click here

Contacts:
Jami Walker

314-579-3342

Copyright © Elsevier Health Sciences

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

Nanomedicine

Arrowhead Pharmaceuticals to Webcast Fiscal 2017 Second Quarter Results April 27th, 2017

New Product Nanoparticle preparation from Intertronics with new Thinky NP-100 Nano Pulveriser April 26th, 2017

Nanoparticle vaccine shows potential as immunotherapy to fight multiple cancer types April 24th, 2017

Arrowhead Presents ARC-520 and ARC-521 Clinical Data at The International Liver Congress(TM) April 20th, 2017

Discoveries

Ultracold atom waves may shed light on rogue ocean killers: Rice quantum experiments probe underlying physics of rogue ocean waves April 27th, 2017

Looking for the quantum frontier: Beyond classical computing without fault-tolerance? April 27th, 2017

Metal nanoparticles induced visible-light photocatalysis: Mechanisms, applications, ways of promoting catalytic activity and outlook April 27th, 2017

Geoffrey Beach: Drawn to explore magnetism: Materials researcher is working on the magnetic memory of the future April 25th, 2017

Announcements

Ultracold atom waves may shed light on rogue ocean killers: Rice quantum experiments probe underlying physics of rogue ocean waves April 27th, 2017

Looking for the quantum frontier: Beyond classical computing without fault-tolerance? April 27th, 2017

Metal nanoparticles induced visible-light photocatalysis: Mechanisms, applications, ways of promoting catalytic activity and outlook April 27th, 2017

Arrowhead Pharmaceuticals to Webcast Fiscal 2017 Second Quarter Results April 27th, 2017

Events/Classes

Arrowhead Pharmaceuticals to Webcast Fiscal 2017 Second Quarter Results April 27th, 2017

National Conference on Nanomaterials, (NCN-2017) April 21st, 2017

Nanomechanics, Inc. Unveils New Product at ICMCTF Show April 25th: Nanoindentation experts will launch the new Gemini that measures the interaction of two objects that are sliding across each other not merely making contact April 21st, 2017

Forge Nano 2017: 1st Quarter Media Update April 20th, 2017

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project